Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-World Deucravacitinib in Chinese Moderate-to-Severe Plaque Psoriasis
ChiCTR2600127242Phase 4Not yet recruiting
- Sponsor
- Department of Dermatology, Xijing Hospital
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of deucravacitinib in plaque psoriasis, sponsored by Department of Dermatology, Xijing Hospital. Primary endpoint: PASI 75/90/100 response rates at weeks 16 and 52. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2600127242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127242.